Gocovri — Competitive Intelligence Brief

Gocovri (AMANTADINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza A M2 Protein Inhibitor. Area: Immunology.

marketed Influenza A M2 Protein Inhibitor Sigma non-opioid intracellular receptor 1 Immunology Small molecule

Target snapshot

Gocovri (AMANTADINE) — Endo.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gocovri TARGET	AMANTADINE	Endo	marketed	Influenza A M2 Protein Inhibitor	Sigma non-opioid intracellular receptor 1	1968-01-01
Aricept	DONEPEZIL	Eisai	marketed	Cholinesterase Inhibitor	Sigma non-opioid intracellular receptor 1	1996-01-01
Naftin	NAFTIFINE	Legacy Pharma	marketed	Allylamine Antifungal	Sigma non-opioid intracellular receptor 1	1988-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	marketed	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Aralen	CHLOROQUINE	Sanofi	marketed	Antimalarial	Sigma non-opioid intracellular receptor 1	1949-01-01
Caraminphen	CARAMIPHEN		marketed	caramiphen	Lysosomal Pro-X carboxypeptidase, Sigma non-opioid intracellular receptor 1, Muscarinic acetylcholine receptor M1
Lamictal	lamotrigine	GSK	marketed	Anti-epileptic Agent [EPC]	5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-01-07 — Lamictal · 8637512 · Formulation · US
• 2040-05-29 — Lamictal · 11596634 · Method of Use · US
• 2040-05-29 — Lamictal · 11612566 · Method of Use · US

Sponsor landscape (Influenza A M2 Protein Inhibitor class)

1. Endo · 1 drug in this class
2. Oregon Health and Science University · 1 drug in this class